These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24976315)

  • 1. Indian generic drug manufacturers in the spotlight.
    Lancet; 2014 Jun; 383(9936):2186. PubMed ID: 24976315
    [No Abstract]   [Full Text] [Related]  

  • 2. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic drug company ordered to upgrade.
    Lewis C
    FDA Consum; 1999; 33(4):37. PubMed ID: 10443182
    [No Abstract]   [Full Text] [Related]  

  • 4. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
    Kay M
    BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
    [No Abstract]   [Full Text] [Related]  

  • 5. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 6. WHO pulls Indian generics off AIDS drugs list.
    Nat Med; 2004 Sep; 10(9):885. PubMed ID: 15340402
    [No Abstract]   [Full Text] [Related]  

  • 7. Supreme Court decision may have major impact on drug industry.
    Spurgeon D
    CMAJ; 1993 Feb; 148(4):629-31. PubMed ID: 8431828
    [No Abstract]   [Full Text] [Related]  

  • 8. The INN crowd.
    Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin.
    Lambert PA; Conway BR
    J Chemother; 2003 Aug; 15(4):357-68. PubMed ID: 12962364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals ... cutting corners rarely pays.
    Hosp Health Netw; 1997 Aug; 71(15):23. PubMed ID: 9274504
    [No Abstract]   [Full Text] [Related]  

  • 13. Making medicines safe.
    Videau JY
    Bull World Health Organ; 2001; 79(2):87. PubMed ID: 11242826
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical quality assessment.
    Florence AT
    Int J Pharm; 2015 Aug; 491(1-2):1. PubMed ID: 26054801
    [No Abstract]   [Full Text] [Related]  

  • 15. A guide for paying less for prescription drugs.
    Johns Hopkins Med Lett Health After 50; 2003 Sep; 15(7):4-5. PubMed ID: 14533592
    [No Abstract]   [Full Text] [Related]  

  • 16. Nature Biotechnology responds.
    Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509756
    [No Abstract]   [Full Text] [Related]  

  • 17. Manufacturing of biopharmaceuticals and implications for biosimilars.
    Wurm FM
    Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic and technological drivers of generic sterile injectable drug shortages.
    Woodcock J; Wosinska M
    Clin Pharmacol Ther; 2013 Feb; 93(2):170-6. PubMed ID: 23337525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic medicines--can quality be assured?
    Drug Ther Bull; 1997 Feb; 35(2):9-11. PubMed ID: 9282412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A divided INN crowd.
    Schellekens H
    Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.